Navigation Links
Transposagen and Cellular Dynamics International Cross-License Technologies for Induced Pluripotent Stem Cells

LEXINGTON, Ky., Jan. 5, 2011 /PRNewswire/ -- Transposagen Biopharmaceuticals, Inc. (Transposagen), a leader in genetic modification technology, announced today that it has entered into a non-exclusive license agreement with Cellular Dynamics International (CDI), the world's largest producer of human induced pluripotent stem (iPS) cell lines and tissue cells for drug discovery and safety.

The license agreement allows CDI to use Transposagen's piggyBac technology in the creation of its products. The piggyBac technology is a highly versatile non-viral method for genetic engineering and stable transgene expression. "We are pleased to be partnering with CDI," said Dr. Eric Ostertag, President and CEO of Transposagen. "Like Transposagen, their products are revolutionizing the drug discovery process."

"CDI is committed to providing human cells derived from iPS cells in the quality, purity, and quantity required by customers, enabling them to concentrate on generating reliable, reproducible, and predictive data and not on creating the cells themselves," said Bob Palay, CDI CEO and chairman of the board. "Toward that end, CDI continues to seek and license in useful technologies, such as piggyBac, that may help improve our manufacturing capabilities." In addition to its iCell™ Cardiomyocytes product line, CDI is planning to launch hepatocytes, neurons, and endothelial cells in the next year.  

The two companies have also agreed to a research and development collaboration.  Transposagen was granted a research license to any cell or product developed by CDI that uses piggyBac for its creation.  Transposagen, the worldwide leader in genetically modified rats, may use CDI's cells to develop "humanized rats," rats that contain organs predominantly consisting of human-derived cells.  Transposagen is developing products expected to improve drug discovery and development by more accurately predicting human response to potential therapeutics at the pre-clinical stage.

About Transposagen BiopharmaceuticalsTransposagen Biopharmaceuticals, Inc., a Lexington, KY based company, is the worldwide leader in the creation of unique genetically modified rat models.  The company's signature products, TKO™ Knockout Rat Models and TGEM™ Rat Models, mimic human diseases and are used for drug discovery and development research. The company also creates custom transgenic rat models to customer specifications. For more information or to request a custom rat model, visit

About Cellular Dynamics International, Inc.Cellular Dynamics International, Inc. (CDI) is a leading developer and marketer of next-generation stem cell technologies for drug development and personalized medicine applications. CDI harnesses the power of pluripotent stem cells and their ability to differentiate into any cell type for world-class drug development tools. In addition, it is the leader in iPSC technology, the production of pluripotent stem cell lines from adult tissue. CDI was founded in 2004 by Dr. James Thomson, a pioneer in human embryonic stem cells from the University of Wisconsin-Madison, and Tactics II Ventures, a Wisconsin-based private equity fund. CDI's facilities are located in Madison, Wisconsin.  See Crawford145 Graham Ave.ASTeCC Bldg., Suite A217Lexington, KY 40506859-428-8561

SOURCE Transposagen Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Transposagen Announces Exclusive License with Charles River Laboratories for p53 and Bcrp TGEM™ Knockout Rat Models
2. Largest Acellular Dermal Allografts for Abdominal Wall Repair Now Available From MTF
3. Tengion Presents New Data Demonstrating Functional Regeneration in a Diabetic Chronic Kidney Failure Model at the International Society for Cellular Therapy
4. Intra-Cellular Therapies Announces the Successful Completion of a Phase Ib/II Study of ITI-007 in Patients with Schizophrenia
5. Cellular Dynamics Partners with iPS Academia Japan, Inc. to In-License Seminal iPS Cell Patent Portfolio
6. Intra-Cellular Therapies Announces the Results of a Phase I PET Study for ITI-007 for the Treatment of Schizophrenia and Other Psychiatric Disorders
7. Cellular Dynamics Announces Commercial Launch of iCell(TM) Cardiomyocytes for Drug Candidate Toxicity Screening
8. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
9. Cellular Dynamics International and VivoMedica Launch the CARDIOTOX Consortium to Validate a Human Cardiac Model for Preclinical Cardiotoxicity Testing
10. Novel Valortim(R) Mechanism of Action Data Presented at the Keystone Symposia on Molecular and Cellular Biology
11. Intra-Cellular Therapies Announces Successful Outcome of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
Post Your Comments:
(Date:11/24/2015)... Nov. 24, 2015  Thanks to a donor with ... Mary,s Medical Center,s Sister Diane Grassilli Center for Women,s ... in San Francisco . ... stepped forward with a gift of $617,320 that allowed ... Mammography with Tomosynthesis and Whole Breast Ultrasound. Tomosynthesis, three-dimensional ...
(Date:11/24/2015)... 24, 2015  Array BioPharma Inc. (Nasdaq: ... Officer, Ron Squarer , will present at ... York.  The public is welcome to participate in ... BioPharma website.Event:Piper Jaffray Annual Healthcare ConferencePresenter:  , Ron ... 2015Time:1:30 p.m. Eastern Time Webcast: , ...
(Date:11/24/2015)... and VANCOUVER, Nov. 24, 2015 /PRNewswire/ - ESSA ... EPIX ) announced today that the first patient ... of EPI-506 as a treatment for metastatic castration-resistant prostate ... and Canada.  --> the ... In the Phase 1/2 clinical trial, ESSA intends ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... "When I underwent ... bras were incredibly uncomfortable," said an inventor from Bronx, N.Y. "In order to ... the patent-pending RECOVERY BRA for added comfort and support. The bra is easier ...
(Date:11/25/2015)... ... November 25, 2015 , ... Bcureful—a non-profit organization devoted to ... raising public awareness of the disorder while helping to bring expert medical care ... to bolster progress at the Tuberous Sclerosis Complex Center at Ann & Robert ...
(Date:11/24/2015)... Florida (PRWEB) , ... November 25, 2015 , ... ... planning and monitoring. Their Care Plan software creates an agreement between the ... patient care plan, including financial, scheduling, monitoring, notification, and projections. Click ...
(Date:11/24/2015)... ... November 24, 2015 , ... Young patients with a ... Dr. Angela Wolfman and Dr. Kedar S. Lele, who are pediatric dentists in ... and fillings, the WaterLase iPlus 2.0™ system causes minimal discomfort and bleeding to the ...
(Date:11/24/2015)... ... November 25, 2015 , ... ... solutions for drugs, biologics, consumer health and global clinical supply services, today announced ... upcoming Clinical Trial Supply East Asia Conference, to be held at the InterContinental ...
Breaking Medicine News(10 mins):